they're consumer businesses and health care units.lanning to eventually spin off that business they're going to come together the move will create a global giant for over-the-counter staples such as advil, tums and toothpaste with $13 billion in annual sales and also free up glaxo and pfizer to concentrate on prescription drugs which are more profitable. this is a fascinating turn of events we're going to hear much more about this deal coming up with the glaxo ceo emma walmsley. that is going to happen at 7:00 a.m. it's interesting only because for so long everybody said you need to have the consumer business next to the -- by the way, much more volatile pharma business >> right >> part of this is function of the margin squeeze on this consumer businesses. pfizer actually couldn't sell that consumer business for a very long time and glaxo is to split it the question is whether you think more of this is going to happen >> you can't gouge on consumer products the way can you with pharmaceuticals. >> especially in the day of amazon that'

the consumer health care business, which i used to run before taking over, has been in e-commerce and consumer health is a much smaller percentage than today. today it is a much smaller percentage. we do have this strong growth in markets like the u.s. and china of course. one of the exciting things is the strength of the business in vitamins, in china and e-commerce. themthe way that we market very directly with the big tech media. how it willdent keep accelerating leadership there. >> brexit, right now, theresa may, how does that affect your business as a practical matter? >> listen, i'm british, i run a global but british company. these are quite difficult times and we are all very much looking forward to more clarity and certainty. in terms of gs k my number one priority with brexit is making sure that u.k. patients and consumers have secured supply, we have been planning that for a long time, looking at it in all scenarios. we will be able to manage through that. beyond brexit, if i can coin a , thee, these businesses new consumer company and the focused farmer factory company wi

which gives probably if successful more yield and the more steady steady income delivering consumer health care business and it said that will be for its balance sheet with this deal in order to be able to invest more in oncology investors thinking it a good idea especially the g s k share going up by leaping up i should say by about seven percent on this occasion some people really welcome that move there will be bought in front of it thank you so much. the european union has agreed on a plan to ban single use plastic a major contributor to c waste according to the e.u. commission around twenty six million tonnes of play. stick wasted generated every year in the e.u. alone less than thirty percent of which is collected for recycling the bad in tends to reduce the amount of plastic waste on land and in the world's oceans the extent of the damage to american life the danger to humans is only slowly becoming a knowledge by policymakers the bad still needs to be ratified by member states but it is already beginning being looked at as a milestone in the fight to reduce plastic waste. a few things a

and then our fifth principle is to promote consumer-driven health care. we have a core underlying belief that a consumer centered health care market defined by choice among health cares and providers, is best at delivering value within the health care -- within the health care market and delivering for the consumer an experience and an outcome that is most pleasing to that individual. and so again, something that i hope and i suspect you'll see in the work that we are delivering and in the thoughts and ideas that i'm sharing with you, that under lies our thinking. but at the end of the day, we define our problems in some very straightforward simplistic ways. we know that our system is expensive and we also know that government policies and regulations often contribute to making it so. we know that our system doesn't always work to the full benefit of patients and consumers. we know that health care markets are not as efficient or as effective as they could be. and we know that contributing to this outcome is the fact that health care consumers don't always

which gives probably if successful more yield than the more steady steady income delivering consumer health care business and it said that it will be for its balance sheet with this deal in order to be able to invest more in oncology investors thinking it a good idea especially the g.s. case you're going up by leaping up i should say by about seven percent on this occasion some people really welcome that move that we bought in front of it thank you so much. on the mobile division of japanese take giant softbank has made its debut on the tokyo stock exchange. it's was one of the world's biggest. ever i.p.o.'s valued at about twenty three billion dollars but shares dipped by as much as ten percent in early trading a public listing as part of soft bank groups attempt to transform itself from a japan based telecoms company to a global high tech investment firm softbank vision found has strong links with the saudi royal family. china is germany's biggest trading partner but there is growing concern about china's appetite for german companies this summer blocked a chinese date for a twenty percent sta

pfizer has agreed to combine consumer health care businesses and a joint venture controlled by the u.kglaxo creating the biggest supplier of over-the-counter medicines in the world. breakdown this deal for us, it is huge. who gets what? >> glaxo get the rhine share, 58% and pfizer get the rest. that is probably because they have the perspective of the ipo three years down the road. business andumer into that medicine business of vaccines and oncology. > in the midterm contributing relatively larger cash flows from this joint venture to continue to fund our number one priority which was the pipeline. we also give visibility to the eventual separation post-integration and as we have further progressed in our pharma pipeline that will allow us to reset the balance sheet. -- very much based on the science of immunology and onetics and new technology one new world leader in consumer health care. >>. 's>> souring the christmas season for retailers. they have lowered their 2019 sales outlook. it was lower at the open by 38%. given a sus was the retailer that was on it for so many years? >> th

. ♪ pfizerosmithkline and have agreed to combine their consumer health care businesses in a joint venturepany glaxo, creating the biggest supplier of over-the-counter medicines in the world. breakdown this deal for us. it's huge, obviously. global locations, who gets what? >> glaxo gets the lions share, 58% of the joint venture, pfizer gets the rest. investors are saying it is probably because they have that perspective of the ipo three years down the road. ups is essentially a split through the medicine business, vaccines and that kind of stuff. >> they are contributing significantly larger cash flows from the joint venture, continuing to fund on priority on the pharma pipeline, and we also give visibility to the eventual separation post integration, and as we've made further progress, that will allow us to reset the balance sheets of two companies to focus u.k. base, one pharma in vaccines, very much a on the science of immunology, and one new world leader in consumer health care. ♪ >> a profit warning from britain's aphis. it tumbled as it lowered its 2019 sales outlook, lower at the o

. >> cvsealtherged with aetna wants to ruchlgize consumer health care with things like digital health records that make care easier to access at pharmacies and providing doctors and nurses on demandvailable online. >> we're excited tosz the new pralgt models come out to help drive better costs afford ability within the health care economy. but a lot of focus on drug pricing. >> the verdict is out on how quickly the new options can deliver on lowering costs for consumerers. but washington will be a b factor in drug pricing in 2019. the tru administration's first proposals to lower medicare drug costs are expected to be mid-year. around the analysts expect more drug regulation to follow. "rghtly business report" i'm bertha moombs, new york. >> ford peace move to are rev up sales. >> the ranger is back and who buys in mid-size pickup in i'm phil lebeau we take you for a test drive with the new ranger t coming up on"nightly business >>> we reported earlier that ford shares got a lift today on reports that china may cut the imports.n u.s. auto well ford is also hoping to get urn of lift fr

based on the sciencef immunology again the et iks andie two technol and the global leader in consumer health care. >> the deal is expected to bete comp in the second half of 2019. the companies are expected to spin off the joint venture in three years. more "nightly business report" frank who will zbloond higher prices help general mills that's where we begin the market folks focus opinion the packaged food company helped improve profitens and offset freight costs. they are working to get rid of older food bras but not specifying which. the stock rose 5%. >>> winnebago reported better than expted earningsn the recent quarter. citing higher sales in the north american recreational business. they raised the quarterly dividend sending the stock 13% higher to 22.67. >>> ee you lie lilly raised the quarrly dividend and issued a stronger than expected profit forecast nex year. the drug maker cites demand for new medicines and the existing drug diabetes franchised are franchise. the stock rose 2% to 109.11. allerganill pull breast implants from the european market following a mandatory request from regu

within the last hour, drug giants glaxosmithkline and pfizer say they'll combine their consumer health carens. the combined unit will have sales of almost $13 billion. and japanese technology giant softbank raised a record amount for its mobile unit in the world's second—biggest—ever stock market flotation, but the shares have slumped in a disappointing debut. we'll be live in the region for the latest. and a christmas dinner with all the trimmings. we'll be finding out from one turkey farmer the challenges facing businesses which are highly seasonal. we would love to hear from you. are you swayed by what is on offer next to the till in the supermarket? a study suggests shoppers buy almost a fifth less junk food when it is removed from the checkout. there has been a reduction in the goods on sale, sweets and the like, by the pills. get in touch to tell us by the pills. get in touch to tell us if you are an impulse shopper. —— by the tills. hello and a warm welcome to business live. there is a lot to fit in. the us central bank, the federal reserve, is due to wind up its final meeting of the

two of your competitors, glaxosmithkline and pfizer, announced this week their merging their consumer health careions. is that a way to get prices in a better state where you actually see companies coming together? >> maybe. that's a combination for over the counter medications, the kind you would just buy off the shelf at walgreens or cvs. really our business is prescription medications where you go to your doctor -- maria: i mean, if you need a prescription for a cancer medication, you're talking about $150,000 a year. >> in some cases. those are the costs. now, that's because r and, the's expensive, there's very few patients with some of these conditions, and the way the economics work is those cancer medications are paying for the r and k for the -- r&d for the next cancer medications. the real issue is out of pocket costs, and we're for change in that model. patients are paying too much out of pocket costs. so the administration's proposed a number of ways to get at this including narrowing the spread between that list price and the net pricing. and we think some of those are good ideas. whe

major deal in the drug sector today pfizer and glaxosmithkline are going to combine their consumer health care. they have plans to eventually spin off that newly combined business now this move will create a global giant for drugstore staples that you know, advil, tums and others. it will have $13 billion in annual sales and also free up glaxosmithkline and pfizer to concentrate more on prescription drugs which are more profitable than over-the-counter. we're going to hear much more about this deal and why they're doing it with emma walmsley, ceo. be sure to catch that interview at 7:00 a.m. eastern time. >>> in other corporate news, japan's biggest ipo ever flopping in the public debut let's get to our reporter live in tokyo with more on softbank mobile >> good morning to you, brian. that's right concerns about the saturation and the domestic telco sector and softbank mobile's exposure really dampened the mood for the debut of the company on the tokyo stock exchange this was japan's largest ipo with more than $23 billion raised it was right up there with the largest ipo of all time which is,

based on the science of immunology, genetics, and new technology, and one world leader in consumer health carek about how you plan to deploy that cash for your prescription drug business. you say organically and in you looking toe buy more in the areas of vaccines and prescription drugs? got -- firste have of all, we are delighted with the announcement to acquire to sorrow. -- tessaro. we think it is a tremendous opportunity not just for gs k, .ut for oncology patients that is an exciting move into specialty months in and to build up -- medicine and to build up our specialty medicine business. we already have a strong commercial team, which we are looking forward to being part of gsk. we have been doing a lot of work over the last 18 months to reshape the group portfolio, whether that be through acquisitions or indeed noncore divestments, is another announcement we made recently, divestments to unilever. ourve always said that number one priority in terms of capital allocation was to invest in our pharma pipeline organically and in organically, but my first priority is to execute with excellen

professionalsare take a look at ways to reduce health care costs and improve consumer choice in the you s. hosted by the american enterprise institute, this is 90 minutes. good morning, everyone. welcome to the american enterprise institute. our conference today is health care that matters. real choices for real competition. i am tom miller. what we are going to do today. yesterday, the trump administration released its report on reforming america's health care system through choice and competition. bywill start with an address the white house advisor about how the report came about. why it is needed, and what sort of policy reforms could help provide higher quality health care at more affordable prices. then, we will hear from two different panels. the first one will take a closer look at what a more fleshed out approach could accomplish. both potential and limitations. tankose of us in the think reflect, even if it works in practice, should it work in theory? our second panel will dive deeper into current health care markets real people in real businesses highlighting what can be done

split,planning for a having agreed to combine consumer health care businesses in a jv, listed in threerum. we will talk about the joint venture with gsk. domestic telecom business had one of the worst first-day declines in japan, falling 14%. softbank stuck to a price rather than a range. and thethe selloff network outage. ge will spin off its second-most profitable business line. it has filed for an ipo of its health care unit. a public filing is likely next spring. the new entity could have an enterprise value of up to $70 billion. that is the bloomberg business flash. nejra: thank you. to recover from its biggest slump since 2016 as slowing global growth is haunting investors. with us is our executive editor for energy and commodities. we outlined the bearish case for oil. what is the bullish case? >> there is one glimmer of hope. with thebia came out budget assuming $80 a barrel, which is courageous. when we run the math, we come up with $95 a barrel they would need to break even on their budget. that may give you pause for thought, but either that is policy, will drive the meaning

energy leading the decline tech, consumer discretionary, health care and consumer staples are down elsewhere like to talk about the january barometer. this is one of wall street's favorite barometers and for good reason it registered only nine major errors since 1950. it has been accurate 75% of the time, better than most wall street saws. every down january on the s&p since 1950 without exception has been preceded by a new or extended bear market, a flat market or at least a 10% correction in other words, as goes january, the rest of the year gets rocky if it is down. with a strong track record and so much market confusion around economic risk like china slog slowing and rate height risks, unfortunately what we're seeing is end of the month jis selling off. that's a clear imprint that tax law selling is real. the hope is that it abates then we had a lot of obviously short selling going on a lot of big names that were heavily shorted were dropping heavily in the first part of december as well i think a good part of yesterday's rally was short covering you look at big names, chesapeake energy

pize per and smith cline they plan to combine their consumer health care units. it creates the world's large pest seller of drugstore staples like advil, et cetera, et cetera et cetera world with largest over the counter drug company will be created by this proposed get together. are they sort of protecting themselves gns against amazon getting into health care is that a move? >> i think it is. but you know everyone is trying to compete with amazon in every sector there is. you have amazon effect right so this is one way to continue to scale. get larger and hopefully cap which you more market share that is their position from the business perspective. when you combine precipitation business over the counter you say diversifying revenue when you split them apart we're catering to investors really it is to have more markets and half going forward so i think -- both stocks are up. also by the way you don't go to the it shall to see anymore to fill your prescription med and buy rolaids so the world that has changed there's no longer synergy between two businesses. >>

tech and health care and consumers led the fall. no sector was left unscathed. goldman sachs was among the big losers after malaysia filed criminal charges linked to the missing billions at 1 mdb. >> every sector on the s&p 500 was in the red with the dow falling 500 points for the second consecutive session. we saw the nasdaq also lose 0.2% losing ground for a third session. s&p futures also pointing lower, down 2%. we have the health care sector taking a big hit. a judge in texas ruling that obamacare was unconstitutional. that led to more volatility in the sector. yields were pressured as we get concerns over growth, trade tensions, geo politics, and we still have the financial sector also leading the decline. let's see how we're shaping up for the market open in asia. >> this tuesday we are bracing for losses after the poor showing on wall street. japanese shares set to resume the climb after slight gains on monday. the nikkei barely hanging on to the year to date gain of 2.6%. in sydney opening lower by a third of 1% after futures fell the most in a week. a

consumer experience first and foremost. they started building and it toppled away the system and it used to look and health care, you can't leave everything up to the consumer and health care, and it raced to the bottom and from the benefits point of view and you need health benefits and i'm a big believer of that. around that, look at what freedom we can create. >> so i think we should work to try to create less of a giant incentive for employers to be the purchaser, but i think that much more impact will come on the payment reform on the supply side, and the symmetry. if you think about the health care spending and the 10% of patients that are super expensive and they're spending $70,000. no american's bank account can absorb that sort of empowerment because they don't have a way to pay for this. >> the drugs that they are using are going to cost 20,000 growing at 10% a year. the hospital -- we have avoidable day, but when we have a patient in the bed you can't avoid that day. so the people that i think have the most leveraged information are actually the primary doctor who when incentivized to think about the cost of care, w

health care costs. a second way is to make it easier for consumers of health care to know the true price of what they are buying, and i would welcome suggestions of how those policy ideas could be implemented, what law to amend, what regulation to change, and any potential downsides to the policy recommendations. i will share these recommendations with senator patty murray, who is the ranking democratic member of the senate health committee, and with all of the members of our committee. i will share the recommendations with senator grassley and senator wyden, who are expected to be the chairman and ranking member of the finance committee. our health committee and the finance committee has shared jurisdiction over health care costs. sometimes that gets in the way of solutions. there's no reason it should. we should all be able to work together in a bipartisan way to address this startling phenomenon that the experts tell us is true, that we're wasting, that we're spending nearly half the money we spend unnecessarily on health care. now we need for the experts to tell us exactly what to do about it. the fe

same. 2018, with at thread on that high-end, i think technology and health care are leading on the very high end. i'm sorry, consumeriscretionary and health care leading on the high-end. up 14, 15% and energy down 12% or so. that is a pretty big gap in terms of performance and yours can look it up on bloomberg to get the exact data, but we expect that to continue so rate sensitive sectors like utilities should perform well. we think financials in 2019 could perform well. are probably going to underperform. the faang stocks in technology sector, materials, and industrials will probably face headwinds. , oliver, right thank you for your insights. we will have more to come here on "bloomberg daybreak: australia." stay with us. paul: i am paul allen in sydney. shery: and i'm shery ahn in new york. you're watching "bloomberg daybreak: australia" president trump says china is sending strong signals about a trade deal, but uncertainty remains over what was agreed upon in front authorities -- when is aries -- buenos aires. let's cross to washington and our congress editor. werea big question is what the subjects discussed a

from insurance to workforce that could be driving up health care costs and examine every possible regulation that might be driving up the prices consumers pay. one of th the babies to separate our efforts from the past reform is our recognition that affordable health care for every american does mean affordable insurance premiums, but most of all it means affordable healthcare prices. under this administration health care reform will be focused on driving down the cost of care not just coming up with a better way to finance it. president trump is not interested in tinkering around the edges of the system. he knows that the poses on americans today and he wants fundamental reform and that is what we will deliver. thank you for your time today and i look forward to the discussion. [applause] thank you very much mr. secretary. you've answered most of my questions. at aei we say we are going to have a fireside. we don't did figuratively we did it literally. [laughter] scott tells me it's for adults over 21 at probably can stay on the market. [laughter] this is going to cause problems in the iowa caucuses if it doesn't light up. you got the

tech and health care and consumers led the fall. no sector was left

>> to find the most cost effective plan, you want to understand what kind of health care consumer you how much health care, how many times do you go to the doctor, what kind of services do you need in a typical year? no one has a crystal ball, you don't know what your health care needs are going to be next year. but you can use your current health and what you did last year or the current year as a guide. so generally, if you're in good health, you don't go to the doctor much, choose a plan that has lower premiums and a higher deductible, because you may never go to the doctor enough to hit that deductible. but if you have a chronic illness or say you're older or have like a big surgery planned for next year, you might be better off with a plan that has a higher premium, what you pay every month, and a lower deductible, because you're going to probably blow past that deductible if you go to the doctor a lot. >> donna, thank you very much for the time and information. >> thanks for talking with me. >> all right. and thank you, michael finney. you can get your cover california questions

health care system function with the discipline and cost-saving benefits of a real market. toget rid of the barriers innovation that keep cost from going down. possibleays to make it for consumers to know the price of the health care service they are buying. if we can make the health care system a true market, that might do more than anything else. >> you said that one of the biggest problems is people don't know the cost. >> that's it. the first is getting rid of the barriers in the way of innovators. nobody knows this. storycretary has a great about he found out a procedure cost several thousand dollars. he got on the website and found out he could get it for $350 from the doctor's office. the way our system is set up, you don't know the price. nobody knows the price. prices are going to come down. >> you talked about over the in january we, will have divided government. we got a sneak peak yesterday. [laughter] you are hoping to do two or three big things, that's a lot. what is one big thing that you believe you can accomplish next year? to sit down with senator murray and figure that out. whenever we agree on something, we can get it done. i talked with her. on my short lis

health care good morning again british based glaxo going to own 68% joint venture u.s. based pfizer 32% shareholders long pushed for glaxo to break into two companies one focused on pharmaceuticals have other consumerg percentage jump, as you can see. . >> nissan facing accusationsiest of carlos glossen glossen, hast of a make over plot the kelly-overed ghosn in japan said her husband was subtle up in a coup mastermind by chief of staff says her husband is innocent, was lured to tokyo despite plans for surgery, to be done in the united states. they are charged with under reporting ghosn compensation on nissan's financial statement look at video to show you body came footage two sheriff's deputies in texas rescuing someone from a burning car after fiery crash rescued this one deputies played unconscious by to a nearby water puddle the heat so strong fire melted part of the officer's uniforms victim luckily in the hospital if stable condition right now. the officers, of course, are okay headlines man a couple heroes there. dagen: indeed thank you so much for that morgan is among your many things that you are consultant i know you you have something you wanted to say about facebook i want to point out

that's cheaper, i mean, look, two of your competitors announced this week they're merging their consumer health carehere you actually see companies coming together? >> maybe. that's a combination for over-the-counter medications, the kind you would just buy off the shelf at walgreens or cvs. really our business is prescription medications where you go to your doctor and need a prescription. maria: if you need a prescription and you're sick, you need a prescription for a cancer medication, you're talking about $150,000 a year. >> in some cases. those are the costs. now that's because r&d is expensive. there's few patients with some of these conditions. and the way the economics work is cancer medications are paying for the r&d for the next cancer medications. the real issue is out-of-pocket cost for patients. and i want to just be clear. we're for change in that model. patients are paying too much out-of-pocket cost. so the administration proposed a number of ways to get at this including narrowing the spread between that list price and the net pricing. and we think some of those are good ideas. whet

it's tilities, real estate, health care, and consumer staples. in fact, real estate, if you're looking for one bright spot this year so far, it's been real estate investment trusts but we'll have to check everything after today >> absolutely. kelly, thanks. >>> now to a bright spot amid this market selloff. shares of the cannabis company tilray surging on a new partnership with anheuser-busch. they're teaming up to research cannabis-infused nonalcoholic drinks for the canadian market here with us now, the president and ceo of tilray. great to see you again >> thanks for having me back >> where do you see the most promise in the beverage market what types of formulations what are the challenges to producing a thc or cbd infused beverage the layperson would think you just sort of put a few drops in and shake it up and there you go but there's much more science to that >> there's a bit more science to it we were excited to announce yesterday a partnership with ab inbev to perform r&d on thc and cbd beverages in canada. some of the complexities invol

the seventy's i got about thirty seconds but for our viewers benefit how can we be smarter health care consumers in this regard great follow up question i think the bottom is a bottom line is is this the bed acacias best medication for me jim any other ideas that would be appropriate for my care and again the whole idea of most patients understand this one pill is not going to be everything so you might use a host of medications that really are going to make you feel that much better is the government doing enough i think the answer is they're doing their best right now we're no we now we're not going to create more addicts are right now the american side of anesthesiologists the operating room we we now know not to give you these pain medications but more importantly we've got a decade of patients that are now have an addiction potential or are truly depend on these medications or we have to care for them too and they are putting a lot of money towards this dr john dombrowski i know you're a busy guy so i appreciate your time merry christmas merry christmas great to be here. come on up if there

consumer staples. i hate to say it, but even utilities. i hate to say it, but even health care. companies like cvs companies like walmart companies like detroit edison. they have good dividend yields solid dividend yields and that gives you a little bit of a curb shan just in case things get sloppy in 2019 i'm relatively optimistic. >> those are specific names for people to check out. joe, i was going to zoom it back out here and say is the recommendation still to remain euro stocks are on track for the second down year in three. the u.s. markets barely had a down year in a decade and this year is unchanged. >> we continue to have more conviction in the u.s. relative to the rest of the world that's really twofold. one from an opportunistic standpoint when you take a look at what's happening with economic growth, this year particularly we're seeing a growing divergence between the u.s. and the rest of the world and you're seeing it in earnings. the second reason is as we near the end of the cycle, and i think there are a lot of signs we are getting closer and closer to the end of

way you will lean, you -- if you are leaning the way we financials, industrials, consumer discretionary, we like health care -if you like those sectors come you have to believe this expansion is not over and that it's unlikely we see a recession over the next 12-15 months. that's the way we are leaning and we think fundamentals are still growth and you will's -- you'll probably see growth 2.7%. we are leaning toward sectors that will benefit from a continuation of the expansion. we do not want them hiding and utilities have done well this year but that's not the kind of thing we think will do well over the next 12 months or so. caroline: you are saying you're not seeing a recession. i'm looking at the economic forecast and we are not seeing a recession from the economists out there. they are seeing 2.6% growth next year. throughst a slow down 2020. how much do you think the economy will support or surprises in 2019? >> i think everyone expects a slowdown from this year. is that the economy hangs in better than the fed. the fed is at 2.3% and we think it will be better than that. the fed might be surprised t

and also to find ways to make it possible for consumers to know the price of the health care service they are buying. and if we could make the health care system a true market, that might do more than anything else to bring -- >> and you said that one of the biggest problems is people don't know the true cost. >> that is it. that is the second thing. the first is get rid of the barriers in the way of innovators, but nobody knows -- secretary acer will be here and he has a great story about how he went for a procedure and found out it cost several thousand dollars and he got on the website and checked around and found out he could get it for $500 in the doctor's office. so the way our system is set up, you don't know the price and if no one knows the price, prices aren't going to come down. >> now, you talked about over the next two years and we're going to -- in january we'll have divided government. we have a little preview -- sneak peek of it yesterday. our divided government. you were hoping to do two or three big things, that is a lot. so maybe pick one of them. what is one big t

i mentioned health care, ticket look at consumer staples -- take a look at consumer staples.index groups gaining and we see all the indexes across europe gaining as well. let's take a look at the mov screen. as far as what we see on the stoxx 600 index, you see a lot more stocks gaining obviously falling.ing -- than up, 67 are down. a little bit of a defensive play on the stoxx 600, as well as you got the staples and drugmakers, the health care stocks rising. on the downside you do see a couple of the financials falling , so lloyd's and barclays k financials falling -- u.k. financials falling, very interesting as this brexit uncertainty continues to hit markets, even markets that are gaining. nejra cehic is down on the green in westminster following this developing story. nejra: as you were sayingnejra:, european markets opening higher at the start of cash equity trading. that has theresa may has to berlin and the hague to discuss her brexit deal after delaying a vote in parliament. joining us now is thanos papasavvas, cio and founder of abp invest. in indiand big moves asset

tech health care consumers leading

consumer staples, health care are the laggards and ones to watch today. health care sector down, universal health services, hca, and boston scientific. and look at johnson and johnson, on pace for the worst day since 2002 the stock selling off after a reuters report says the company knew for decades raw talc and finished powders sometimes tested positive for small traces of asbestos. >> thanks. big move for that stock. >>> a key theme for the holiday season, physical retailers offering convenience with check out with an employee throughout the racks, without going to a register some will be checking out without the help of a human at all. courtney reagan joins us from sam's club in dallas with more on this story. courtney >> reporter: good morning, morgan we have ten days left until christmas. time running short to check off the list imagine going to a retailer where you don't have to check out at all that could make it easier for you. that's what sam's is hoping. at the sam's club in dallas, it is a store and tech lab. walmart owned wholesale club used t

keeps cost from going down and to find ways to make it possible for consumers to know what they are buying if we can make that health care system a true market that could be more than anything. >> you said one of the biggest problems is people don't know. >> that is the second thing first is get rid of the barriers but nobody knows this secretary a czar how he went for a procedure that he got on the website and checked around and thought he could get it for $500 at the doctors office if nobody knows the price over the next two years you were hoping to do two or three big things what's one thing you could accomplish next year quick. >> we have to sit and figure that out if we agree on something we can get it done. i have already talked with her in my short list is reducing healthcare cost. i have sent these letters they say give us something specific to do. what we are focusing on is make the system more of a market to get rid of barriers and if we could find a way to make it possible for those of us who by healthcare services every day to know the price of what we pay for is the single most important thing i could focus